Evofem Biosciences, Inc. entered into Distributorship Agreement with Clovis Davis Pharmaceuticals, LLC. (effective 2026-04-24).
“On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.”
Material Agreements
Evofem Biosciences, Inc. amended Fourth Amendment with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (together, Adjuvant) (effective 2026-04-10).
“On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).”
Material Agreements
Evofem Biosciences, Inc. terminated Termination Agreement with Windtree Therapeutics, Inc. (effective 2026-03-13).
“the Company and Windtree entered into a Termination Agreement (the “Termination Agreement”) pursuant to which the parties mutually consented to the termination of the Agreement, effective as of such date.”
Governance Changes
Evofem Biosciences, Inc.: Stockholders approved a resolution to amend the Certificate of Incorporation to effect a one-time reverse stock split of Common Stock at a ratio between 1-for-500 and 1-for-1,500, at any time before November 26, 2026 (effective 2026-11-26).
“At the Annual Meeting, the Company’s stockholders approved a resolution as previously approved by the Company’s Board of Directors (“Board”) to amend the Company’s existing Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a one-time reverse stock split of the Company’s Common Stock, to effectuate a reverse stock split of the outstanding shares of the Company’s Common Stock by a ratio of not less than 1-for-500 and not more than 1-for-1,500 at any time before November 26, 2026.”
Governance Changes
Evofem Biosciences, Inc.: Filed Certificate of Designations creating Series G-1 Preferred Stock, amending Articles of Incorporation (effective 2025-08-22).
“On August 22, 2025 the Company filed the Certificate of Designations creating the Series G-1 Preferred Stock.”
Listing & Compliance Notices
Evofem Biosciences, Inc. received a otc deficiency notice notice regarding minimum bid price.
“January 6, 2025, Evofem Biosciences, Inc. (the “Company”) received a written notice (the “OTC Notice”) from the OTC Markets Group (“OTC”) notifying the Company that, because the closing bid price for the Company’s common”
Earnings Releases
Evofem Biosciences, Inc. reported the three months ended March 31, 2024 results: revenue $3.6 million, net income loss from operations improved to $2.8 million.
“15.4 million beneficiaries. Effective July 1, 2024, Evofem will pay a 7.4% lower rebate to Medi-Cal on Phexxi prescriptions dispensed to its beneficiaries. ● Net sales were $3.6 million for the first quarter of 2024, reflecting anticipated cyclical softness following the wholesale acquisition cost (WAC) increase on January 1, 2024, and the impact of the”
Material Agreements
Evofem Biosciences, Inc. amended Merger Agreement with Aditxt, Inc. valued at Reinstated and amended Merger Agreement via Fourth Amendment, including $1,000,000 initial payment, (effective 2024-05-02).
“On May 2, 2024, the Company, the Merger Sub and Aditxt entered into the Reinstatement and Fourth Amendment to the Merger Agreement (the "Fourth Amendment") in order to waive and amend, among other things, the several provisions listed below.”
Material Agreements
Evofem Biosciences, Inc. terminated Merger Agreement with Aditxt, Inc. valued at Company terminated Merger Agreement effective April 26, 2024 in accordance with Section 8.1(f) of th (effective 2024-04-26).
“On April 26, 2024, the Company delivered a termination notice to Aditxt notifying it that the Company was exercising its right to terminate the Merger Agreement effective April 26, 2024 (the "Termination Notice"), in accordance with Section 8.1(f) of the Merger Agreement, as revised in the third amendment to the Merger Agreement, made on February 29, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.